Aridis Pharmaceuticals Inc ARDS

NAS: ARDS | ISIN: US0403341045 28/04/2025

0,000 USD (0,00%)

(0,00%) 28/04/2025

Grafiek Aridis Pharmaceuticals Inc

Grafiek Aridis Pharmaceuticals Inc

1 dag1d 0,00%
1 week1w 0,00%
1 maand1m 0,00%
3 maanden3m 0,00%
6 maanden6m -50,00%
1 jaar1j -99,83%
5 jaar5j -100,00%

Aridis Pharmaceuticals Inc in het nieuws

Toon enkel gratis nieuws

4 oktober 2022 · Aridis Announces the Closing of Patient Enrollment in the AR-301 Global Phase 3 Superiority Study · Persbericht

27 september 2022 · Aridis Pharmaceuticals Announces Withdrawal of Public Offering of Common Stock · Persbericht

26 september 2022 · Aridis Pharmaceuticals Announces Proposed Public Offering of Common Stock · Persbericht

16 augustus 2022 · Aridis Pharmaceuticals Announces Second Quarter 2022 Financial Results and Business Update · Persbericht

10 augustus 2022 · Aridis' Pan-Coronavirus, Inhaled Monoclonal Antibody Cocktail AR-701 Is Protective in Non-Human Primates · Persbericht

3 juni 2022 · Aridis Pharmaceuticals CEO to Participate in a Fireside Chat Presented by Maxim Group LLC and Hosted by M-Vest on June 7 · Persbericht

16 mei 2022 · Aridis Pharmaceuticals Announces First Quarter 2022 Financial Results and Business Update · Persbericht

1 april 2022 · Aridis Pharmaceuticals Announces 2021 Fourth Quarter and Year-End Financial Results and Business Update · Persbericht

17 februari 2022 · Aridis' Pan-Coronavirus Monoclonal Antibody Cocktail AR-701 Is Protective in COVID-19 Omicron Infected Animals · Persbericht

27 januari 2022 · Aridis Pharmaceuticals Receives Funding to Evaluate Inhaled Monoclonal Antibodies to Block Influenza and SARS-CoV-2 Transmission · Persbericht

Profiel Aridis Pharmaceuticals Inc

Gezondheidstechnologie

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe